Abstract
Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, risk factors, presentation, diagnosis, management, prognosis, staging, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.
| Original language | English |
|---|---|
| Pages (from-to) | 185-204 |
| Number of pages | 20 |
| Journal | Expert Review of Ophthalmology |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jan 1 2014 |
Fingerprint
Keywords
- BRAF inhibitors
- Conjunctival malignant melanoma
- Dabrafenib
- IFNa-2b
- Ipilimumab
- Melanoma mitomycin C
- Ocular neoplasm
- Vemurafenib
ASJC Scopus subject areas
- Ophthalmology
- Biomedical Engineering
- Optometry
Cite this
Management of conjunctival malignant melanoma : A review and update. / Wong, James R.; Nanji, Afshan A.; Galor, Anat; Karp, Carol.
In: Expert Review of Ophthalmology, Vol. 9, No. 3, 01.01.2014, p. 185-204.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Management of conjunctival malignant melanoma
T2 - A review and update
AU - Wong, James R.
AU - Nanji, Afshan A.
AU - Galor, Anat
AU - Karp, Carol
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, risk factors, presentation, diagnosis, management, prognosis, staging, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.
AB - Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, risk factors, presentation, diagnosis, management, prognosis, staging, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.
KW - BRAF inhibitors
KW - Conjunctival malignant melanoma
KW - Dabrafenib
KW - IFNa-2b
KW - Ipilimumab
KW - Melanoma mitomycin C
KW - Ocular neoplasm
KW - Vemurafenib
UR - http://www.scopus.com/inward/record.url?scp=84901254588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901254588&partnerID=8YFLogxK
U2 - 10.1586/17469899.2014.921119
DO - 10.1586/17469899.2014.921119
M3 - Article
VL - 9
SP - 185
EP - 204
JO - Expert Review of Respiratory Medicine
JF - Expert Review of Respiratory Medicine
SN - 1747-6348
IS - 3
ER -